Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.

Citation:
SA, I., G. R, E. - G. EA, S. O, M. HT, H. H, G. B, El-Shinawi, M. MM, and G. M, "Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.", Mol Cancer., vol. 16, issue 1, pp. 57, 2017.